Guardant Health Investor Presentation slide image

Guardant Health Investor Presentation

NILE: Guardant360 vs standard of care in 1st-line NSCLC Readout of primary endpoint expected in 1H 2019 300 NSCLC Patients Prospective, Multi-Center Trial Standard of Care Tissue Testing + GUARDANT 360 ↓ Detection of NCCN Biomarkers with Tissue Testing VS Detection of NCCN Biomarkers with GUARDANT,360 12 GUARDANT™
View entire presentation